News

Alphabet's forward P/E is historically low and 28.11% below Nasdaq's, making it an attractive buy at current levels. Click ...
Alphabet's AI integration, robust cash flow, and profitable Google Cloud make it a top investment choice. See more on GOOG ...
Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
By itself, Alphabet's new Gemini model may not be a catalyst for the stock, but it is another building block for a company that is showing that it's an innovator. Meanwhile, its recent announcement ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...
We recently published a list of 10 AI Stocks Dominating the News This Week. In this article, we are going to take a look at where Alphabet Inc. (NASDAQ:GOOGL) stands against other AI stocks ...